1. A Novel Humanized Model of NASH and Its Treatment With META4, A Potent Agonist of MET
- Author
-
Andrew W. Duncan, Yong-Kook Kwon, Arman Zarnegar, Xinping Tan, Marie C. DeFrances, Evan R. Delgado, Jihong Ma, and Reza Zarnegar
- Subjects
HFD, high-fat diet ,HGF antagonist ,uPA, urokinase type plasminogen activator ,NK2 ,RC799-869 ,NK1 ,Pathogenesis ,Liver disease ,Mice ,RD, regular diet ,PCR, polymerase chain reaction ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,HGF ,Original Research ,Metabolic Syndrome ,Hepatocyte Growth Factor ,FAH, fumarylacetoacetate hydrolase ,Humanized Liver ,Gastroenterology ,NASH ,Diseases of the digestive system. Gastroenterology ,Type 2 Diabetes ,PAI-1, plasminogen activator inhibitor-1 ,MET ,Hepatocyte growth factor ,Signal transduction ,Liver cancer ,NASH, nonalcoholic steatohepatitis ,medicine.drug ,Liver Cancer ,FAH Mice ,Diet, High-Fat ,Fatty Liver Disease ,digestive system ,HGFAC, HGF activator ,NAFLD ,NTBC, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione ,medicine ,Animals ,tPA, tissue type plasminogen activator ,High-fat Diet ,Hepatology ,business.industry ,nutritional and metabolic diseases ,medicine.disease ,digestive system diseases ,Transplantation ,Cancer research ,Hepatocytes ,HGF, hepatocyte growth factor ,NAFLD, nonalcoholic fatty liver disease ,Metabolic syndrome ,business - Abstract
Background & Aims Nonalcoholic fatty liver disease is a frequent cause of hepatic dysfunction and is now a global epidemic. This ailment can progress to an advanced form called nonalcoholic steatohepatitis (NASH) and end-stage liver disease. Currently, the molecular basis of NASH pathogenesis is poorly understood, and no effective therapies exist to treat NASH. These shortcomings are due to the paucity of experimental NASH models directly relevant to humans. Methods We used chimeric mice with humanized liver to investigate nonalcoholic fatty liver disease in a relevant model. We carried out histologic, biochemical, and molecular approaches including RNA-Seq. For comparison, we used side-by-side human NASH samples. Results Herein, we describe a “humanized” model of NASH using transplantation of human hepatocytes into fumarylacetoacetate hydrolase-deficient mice. Once fed a high-fat diet, these mice develop NAFLD faithfully, recapitulating human NASH at the histologic, cellular, biochemical, and molecular levels. Our RNA-Seq analyses uncovered that a variety of important signaling pathways that govern liver homeostasis are profoundly deregulated in both humanized and human NASH livers. Notably, we made the novel discovery that hepatocyte growth factor (HGF) function is compromised in human and humanized NASH at several levels including a significant increase in the expression of the HGF antagonists known as NK1/NK2 and marked decrease in HGF activator. Based on these observations, we generated a potent, human-specific, and stable agonist of human MET that we have named META4 (Metaphor) and used it in the humanized NASH model to restore HGF function. Conclusions Our studies revealed that the humanized NASH model recapitulates human NASH and uncovered that HGF-MET function is impaired in this disease. We show that restoring HGF-MET function by META4 therapy ameliorates NASH and reinstates normal liver function in the humanized NASH model. Our results show that the HGF-MET signaling pathway is a dominant regulator of hepatic homeostasis., Graphical abstract
- Published
- 2021